



December 04, 2025

Company name: Nippon Soda Co., Ltd.
Name of representative: Eiji Aga
Representative Director and President
(Securities code: 4041; TSE Prime Market)
Inquiries: Toyonobu Katagishi
Manager of General Affairs Dept.
(Telephone: +81-3-6366-1920)

Notice of Additional Investment in SENTAN Pharma Inc.

Nippon Soda Co., Ltd. (hereinafter "the Company") is pleased to announce that it has made an additional investment in SENTAN Pharma Inc. (Head Office: Fukuoka City, Fukuoka Prefecture; Representative Directors: Masaaki Matsubara and Tomoko Nagai; hereinafter "SENTAN Pharma"), with which the Company entered into a capital and business alliance agreement in January 2024, for the purpose of further expanding its business in the healthcare field and strengthening the capital and business alliance relationship. As a result, the Company has become the largest shareholder of SENTAN Pharma.

1. Background and Purpose of Additional Investment

Since entering into a capital and business alliance agreement with SENTAN Pharma in January 2024, the Company has been promoting joint development in the healthcare field. Subsequently, given the steady progress in collaboration in the animal health field and the pharmaceutical development pursued by SENTAN Pharma, the Company has determined that strengthening the capital and business alliance relationship and accelerating collaboration will contribute to enhancing the corporate value of the Nippon Soda Group.

2. About SENTAN Pharma Inc.

Company Name	SENTAN Pharma Inc.
Location	2-1 Shimokawabata-machi, Hakata-ku, Fukuoka City, Fukuoka Prefecture, Japan
Representative	Chairman: Masaaki Matsubara President: Tomoko Nagai
Established	Feb 8, 2007
Business scope	Research and development of pharmaceuticals, medical devices, quasi-drugs, and manufacture and sale of health foods

SENTAN Pharma is a drug discovery venture company that develops therapeutics for various diseases using its proprietary nano- and microparticle formation technologies. The company operates both a pharmaceutical drug discovery business and a preventive medicine business focused on health foods. In the drug discovery business, SENTAN Pharma conducts joint

research and development and provides pharmaceutical development support based on nanoparticle formation technology aimed at improving solubility and absorption and reducing dosage, as well as microparticle formation technology for long-acting sustained-release injections that maintain drug efficacy over an extended period with a single administration. In the preventive healthcare business, the company has developed "Foodicle," an edible nanoparticle with significantly improved absorption through nanoparticle formation technology, and has launched three products to date.

3. Future Prospects

With this additional investment, the Company has become the largest shareholder of SENTAN Pharma and has entered into a new capital and business alliance agreement with SENTAN Pharma. The Company will promote the following business developments:

① **Early Entry into Animal Health Business**

The Company will advance joint development of livestock feed products and pet supplements, and will begin sales as the Company's animal health products from 2026, promoting sales both domestically and internationally.

② **Full-scale Entry into CDMO* Business in the Pharmaceutical and Veterinary Drug Fields**

Utilizing SENTAN Pharma's core technologies of nano-particulation and microencapsulation, the Company aims to achieve full-scale entry into the CDMO business for nano-particulation processing of active pharmaceutical ingredients and microencapsulated sustained-release injectable formulations in the pharmaceutical and veterinary drug fields.

*CDMO (Contract Development and Manufacturing Organization): Contract development and manufacturing organization for pharmaceuticals.

③ **Establishment of Fine Particle Manufacturing Technology**

The Company will introduce SENTAN Pharma's technologies and aim to establish a manufacturing system for fine particle formulations and achieve mass production.

The Company's mission is to create new value through the power of chemistry and increase corporate value by contributing to society. Through strengthening the capital and business alliance relationship with SENTAN Pharma, the Company aims to create new corporate value by promoting open innovation, contribute to solving social issues related to healthcare, and achieve sustainable growth of the Nippon Soda Group.